All News
#ACR BEST Abstracts from San Diego – Day 1
The RheumNow faculty reporters have been scouring the meeting for what they believe to be the best presentations from the first day at ACR 2023 in San Diego. From hundreds of online presentations, the poster floor and the plenary podium, here are some of the best abstracts from Sunday Nov. 12th. You can spot these on Twitter by looking for the (#ACRbest) hashtag.
Read Article
#irAE Baseline immune suppression does NOT protect against worsening synovitis flares when using check point inhibitors in Pts with established #inflammatory #arthritis #ACRbest #ACR23 @ACRheum @RheumNow abst1075 Data from #CanRIO database https://t.co/lOCf8Tbgta
Janet Pope ( View Tweet)
#ACR23 Abs #2199 large RL study: SEC retention rates after 4 yrs approx. 50% in axSpA and PsA pts. Bio-naïve pts had higher retention, remission & response rates than pts with prior b/tsDMARD exposure, particularly in axSpA. https://t.co/Eq5BwILK3D @rheumnow https://t.co/slho6yAwtQ
Dr. Rachel Tate ( View Tweet)
PtGA and PhGA were aligned in most encounters in PsA. PtGA >PhGA disagreement was driven by pain, fatigue, and physical health being weighed more by Pts than Phs. PROs matter! #ACR23 Abs #2234 https://t.co/0r7gjx0JS6 @rheumnow https://t.co/BuGDicwBiB
Dr. Rachel Tate ( View Tweet)
Eder et al. Women with PsA have worse outcomes with advanced therapies. OR favours men for ACR 20, IL-17i (OR 1.76), IL-23i (OR 1.46), IL-12/23i (OR 2.66) and TNFi (OR 1.67). Maybe not JAKi (OR 1.09). Placebo OR 1.04. Abstr#1687 #ACR23 @RheumNow https://t.co/bkDmmmYECF https://t.co/VBLnJzhcaY
Richard Conway ( View Tweet)
Evidence of window of opportunity concept in PsA. Certainly >52 weeks delay associates with worse outcomes. <12 weeks and 12-52 weeks similar. Abstr#1641 #ACR23 @RheumNow https://t.co/fMb3D9zl8B https://t.co/rHu29Eflo0
Richard Conway ( View Tweet)
Window of opportunity in PsA
Higher time to diagnosis in
-female
-higher enthesitis
-less swollen joints
-lower CRP
If diag > 52 wks, over 3 yrs
Less MDA, less remission
Worse HAS-DI, PSAID
Same Rx progression
No diff between <12 wk & 12-52 wk
@RheumNow #ACR23 ABST1641 https://t.co/Ek1CDFwENg
Aurelie Najm ( View Tweet)
Haberman et al. In PsA non-white patients have higher tender (but not swollen) joint counts, higher radiographic axial disease, worse skin disease. Women have higher RAPID-3 scores. Abstr#1639 #ACR23 @RheumNow https://t.co/4SL7FLzNuE https://t.co/sVwk1VaSLS
Richard Conway ( View Tweet)
#ACR23 Abs #1641 found early referral & dx in PsA associated w/ better clinical outcomes. MDA & DAPSA remission over 3 years less likely after > 52 weeks from symptom onset to dx. Likely delays in females w/ less swollen joints & lower CRP/ ESR https://t.co/meVQ1UisKY @rheumnow https://t.co/EBN7wJfjzK
Dr. Rachel Tate ( View Tweet)
Izokibep, IL-17Ai, #ACR23 abs #1688 demonstrated ACR70 in 52%, PASI100 in 71% and enthesitis complete resolution in 89% at week 46. Well tolerated, no dose-related AEs, similar safety with other IL-17Ai https://t.co/TQAIVa9H2j @rheumnow https://t.co/ihzxnuAsWw
Dr. Rachel Tate ( View Tweet)
MOSAIC study: #ACR23 Abs #1690 finds APR reduces clinical and objective MRI indices in PsA, confirming an effect of APR on clinical and inflammatory manifestations of PsA. https://t.co/F5D81FF1tj @rheumnow https://t.co/rGglgiOyDg
Dr. Rachel Tate ( View Tweet)
Apremilast associated with improvement in LDL, obesity and diabetic A1c in PsA pts, especially in those with worse levels at baseline!
Can consider apremilast use in PsA with high burden of comorbid cardiometabolic diseases
@RheumNow #ACR23 Abs#1414 https://t.co/fL9UWcaZgG
Robert B Chao, MD ( View Tweet)
Can US differentiate pain? In #ACR23 Abs. #1388 PsA pts who have pain & inflammatory enthesitis on US, process pain differently than the US negative patients, despite the induction of pain or discomfort on all groups. Interesting finding. https://t.co/YcccLoQCBj @rheumnow https://t.co/o94bMwndxX
Dr. Rachel Tate ( View Tweet)
In this updated pooled safety analysis from clinical trials of PsO, PsA & axSpA pts given SEC 150 &/or 300mg SC (ADeodhar et al)
⬆️freq AEs: nasopharyngitis & URTI
Low EAIRs/100pt yrs for IBD, malignancies & MACE
No new safety signals
Reassuring data.
#ACR23 ABST1436 @RheumNow https://t.co/guF0gC4hQM
sheila ( View Tweet)
Quick curmudgeonly complaint
WHY are we doing 316 week extensions? That's 292 weeks of $$$ data... for what?
1. Insufficient N to assess meaningful safety signals
2. Open label, no comparator
It's just a very very expensive observational study
@RheumNow #ACR23 Abstr1434 https://t.co/Thj1XjeAn1
Mike Putman EBRheum ( View Tweet)
Proof-of-concept study: when PsA pts w/Achilles enthesitis & +US findings underwent pain induction, they showed ⬆️activity in the OBF gyrus, ant cing, left PCG, SMG, STG an left PC lobule vs. US- grp.
PsA pts w/+US process pain differently than US-
#ACR23 ABST1388 @RheumNow https://t.co/ScXA17LHPa
sheila ( View Tweet)
Pooled safety analysis of 48 phase II/III/IV trials on secukinumab for tx of PsO, PsA and axSpA
Well tolerated
No new long term safety signals
IBD, malginancy, MACE remain low
@RheumNow #ACR23 Abs#1436 https://t.co/6dzdO5Vpuc
Robert B Chao, MD ( View Tweet)
Long-term safety of risankizumab in PsA and PsO pts
Over 5k pts, over 4 years
Rates of AEs remained low
malignancy incidence remains low
@RheumNow #ACR23 Abs#1422 https://t.co/GBFke3XmQD
Robert B Chao, MD ( View Tweet)
Patient perspective: PP09 at #ACR23
"Mindfulness helps me experience less suffering over pain" in patient with PsA + fibromyalgia.
⭐️Consider recommending mindfulness training such as mindfulness based stress reduction
@RheumNow https://t.co/DHwduvTPZL
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
The places to look for #enthesitis in #PsA in foot/ankle
#ACR2023 https://t.co/KxD7i5l5gS
Dr Gurdeep S Dulay ( View Tweet)
